Stefanos Theoharis, an experienced cell therapy executive, has joined Bone Therapeutics SA as chief business officer to help partner the company’s programmes, in-license assets and advance the proprietary portfolio. Bone Therapeutic’s lead product for bone regeneration is poised to start a proof-of-concept clinical trial. Dr Theoharis previously led business development at Cell Medica Ltd and before that, was CBO at apceth GmbH, a cell therapy developer and contract manufacturer. He holds an MSc in molecular medicine and a PhD in pathology and immunology from Imperial College London, UK.
Bone Therapeutics announced the appointment on 26 March 2020.
Copyright 2020 Evernow Publishing Ltd.